Description
Tirzepatide (GIP and GLP-1 Receptor Dual Agonist) | 30 mg
Bio Glow Wellness · Research use only
Research use only. Not for human or animal consumption. Bio Glow Wellness supplies this compound to laboratories, universities and independent researchers for in vitro and analytical work. It is not a medicine, a supplement, or a therapeutic product, and it is not sold for any personal use.
About Tirzepatide
Tirzepatide is a 39 residue synthetic peptide built on the backbone of GIP, one of the two hormones the gut releases after a meal, and engineered to activate both the GIP receptor and the GLP-1 receptor. A long fatty diacid chain is attached partway along the molecule. That chain is not decorative. It binds albumin in circulation and is the reason the molecule persists far longer than the hormone it was derived from.
This sequence corresponds to an approved prescription medicine sold under brand names in the United States and elsewhere, prescribed and supervised by clinicians for defined conditions. That approval belongs to a formulated, regulated, quality controlled medicine. It does not extend to a research powder in a vial, and this material is supplied strictly as laboratory material for research use. Bio Glow Wellness does not supply it for any human use and makes no claim about it in a person.
Tirzepatide Explained Simply
Read this first. The section below is written in ordinary language so that a non-specialist can follow what this compound is and where it shows up in the scientific record. It is not medical advice, it is not a claim that the compound does anything in a person or an animal, and it is not a protocol. Bio Glow Wellness sells Tirzepatide for laboratory research only.
The short version
A 39 residue engineered peptide that activates two gut hormone receptors at once. Supplied as a laboratory research chemical only.
What it actually is
After a meal the gut releases signalling hormones that tell the pancreas what is arriving. Two of them, GIP and GLP-1, act through separate receptors. Earlier compounds in this field targeted GLP-1 alone. Tirzepatide was designed to hit both receptors with a single molecule, which is why it is described as a dual agonist. Achieving that required a sequence that is neither hormone exactly but is recognized by both receptors, plus two unnatural amino acids and a fatty chain to keep it in circulation.
Where it turns up in research
- Incretin receptor pharmacology, GIP and GLP-1
- Receptor selectivity and biased signalling studies
- Pancreatic islet and beta cell research in culture
- Metabolic research in animal models
- Albumin binding and half life extension chemistry
- Analytical method development for large acylated peptides
What the published work shows so far
The published pharmacology characterizes the compound as an agonist at both incretin receptors with differing potency at each, and documents the role of the fatty acid chain in extending circulating half life. A substantial clinical literature exists for the approved medicine in its licensed indications. That literature concerns a regulated product administered under medical supervision and is not evidence about a research powder. Bio Glow Wellness makes no claim about this material in any person.
Why researchers keep returning to it
It is the reference compound for dual incretin receptor agonism, a design approach that has reshaped an entire pharmacological field. A laboratory characterizing new receptor ligands or studying how signalling at two receptors combines needs a well documented comparator, and this is it.
What nobody can claim about Tirzepatide
- It cannot be described as a weight loss product, a diabetes treatment, a metabolic therapy or a treatment for any condition.
- The approved medicine’s clinical evidence cannot be presented as evidence about a research powder. They are not the same product and this material has no clinical characterization.
- It cannot be described as safe, appropriate or suitable for human use in this form, and it is not supplied for that purpose.
- It cannot be sold or described as a supplement, a compounded preparation or a drug.
- This research material is not approved by the FDA for any use, and unsupervised use of research chemicals carries risks no page can quantify.
Where the information above comes from
Identifiers, composition and the nature of the acylation come from public chemistry references and published pharmacology. Clinical material in the literature concerns an approved, formulated, supervised medicine. Read it as such, and do not carry its conclusions across to laboratory material.
Physical and Chemical Data
Reference values for Tirzepatide (GIP and GLP-1 Receptor Dual Agonist). Lot-specific results are on the Certificate of Analysis supplied with the batch.
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4,813.5 g/mol |
| Chain length | 39 residues, with a fatty diacid side chain |
| Sequence | 39 residue chain based on the GIP sequence, containing two aminoisobutyric acid residues and a C20 fatty diacid conjugated through a linker to lysine at position 20, C terminal amide |
| CAS number | 2023788-19-2 |
| Classification | Synthetic acylated peptide acting as an agonist at both the GIP and GLP-1 receptors |
| Synonyms | LY3298176 · Dual incretin receptor agonist |
| Appearance | White to off-white lyophilized solid |
| Reported solubility | Reported soluble in water at laboratory working concentrations. Solubility is pH dependent |
Molecular Design and Stability
Three design decisions are visible in the molecule. The backbone is GIP based but altered at positions that determine receptor recognition, so that it engages the GLP-1 receptor as well. Two aminoisobutyric acid residues, which do not occur in natural proteins, block the enzymatic trimming that destroys both native hormones within minutes. And a C20 fatty diacid is attached through a linker to a lysine side chain, giving the molecule a grip on circulating albumin. The first change creates the dual activity, the second and third make it last.
The lyophilized solid is the stable form and should be kept sealed, cool and dry. In solution the acylated chain makes solubility behaviour pH dependent and the molecule is prone to aggregation at higher concentrations, which is a practical difference from the short peptides in this catalogue. Prepare fresh at the working concentration, avoid repeated freeze and thaw cycles, and do not store the vial reconstituted.
Laboratory Applications
Researchers working with this compound have used it to investigate:
- GIP and GLP-1 receptor binding and functional assays
- cAMP accumulation studies in receptor expressing cell lines
- Biased signalling and beta arrestin recruitment assays
- Pancreatic islet and beta cell culture studies
- Rodent models of metabolic regulation
- Albumin binding measurement and half life extension chemistry
These are descriptions of published experimental work. They are not suggestions for what a buyer should do with the material, and they are not evidence of any effect outside the model in which it was observed.
What the Literature Covers
1. Dual agonism as a design goal
Building one molecule that activates two related but distinct receptors is a hard medicinal chemistry problem, and this compound is the most prominent solved example. The pharmacology literature on how the two signals combine is the most scientifically interesting part of the record.
2. Albumin binding
The fatty diacid chain is a general strategy rather than a one off. By binding albumin, the molecule travels with a long lived carrier protein instead of being cleared as a free peptide. The same approach appears across several modern peptide drugs.
3. Unnatural residues
Aminoisobutyric acid does not occur in natural proteins, and the enzymes that clip peptides do not recognize it. Its inclusion at two positions is what protects the chain from the degradation that limits the native hormones.
4. Receptor potency is not equal
Published pharmacology reports different potency at the two receptors rather than balanced activity. That imbalance is itself a research subject, since it determines which signalling contributions dominate under given conditions.
5. An approved medicine exists and this is not it
This distinction carries more weight for this compound than for anything else in the catalogue, because the approved product is widely known and widely discussed. A research powder has no formulation, no dosing, no sterility assurance for administration, no supervision and no clinical evidence behind it. Treating the two as the same thing is the central error to avoid.
Batch Documentation
Every shipment is tied to the paperwork for the lot it came from.
- A Certificate of Analysis is supplied for the batch shipped, where one is available for that lot.
- The COA states the analytical methods used and the results for that specific lot. It is the authoritative record for the material in hand.
- Figures on a COA describe one batch only. They are not carried over to other lots and should not be read as a standing specification for the product.
- Testing is performed by an independent third-party analytical laboratory. The laboratory is named on the certificate.
- Published certificates are collected in the Certificate of Analysis library. Our guide to reading a certificate explains what each section reports and what it does not.
Storage and Handling Guidance
General handling practice for lyophilized research peptides:
- Keep the sealed vial cool, dry and out of direct light.
- For anything beyond short-term storage, refrigerate or freeze in line with the handling standard your laboratory already follows for lyophilized material.
- Limit how often a vial is opened and closed. Each cycle exposes the powder to ambient humidity.
- Reconstituted material is generally less stable than the dry powder. Where a study calls for solution, common practice is to aliquot to the working volume rather than store the whole vial in solution.
- Let a refrigerated vial reach room temperature before opening it, so condensation does not form on the contents.
Bio Glow Wellness does not supply reconstitution volumes, concentrations, schedules or any other instruction for administration to a person or an animal. Handling decisions belong to the researcher and to the standards of the facility doing the work.
Common Questions
Can this be used by a person?
No. It is supplied for in vitro laboratory research only. It is not approved for human or veterinary use, it is not a drug or a supplement, and Bio Glow Wellness will not supply it for any other purpose.
What do researchers use Tirzepatide for?
It is used as a reference agonist in incretin receptor pharmacology, in receptor signalling and selectivity studies, and in metabolic research in cell and animal models. The study design determines the application.
Do you provide dosing or reconstitution instructions?
No. Bio Glow Wellness does not publish dosing, administration or protocol guidance of any kind. Study design, handling and safety practice are the responsibility of the researcher and their institution.
Is a Certificate of Analysis included?
Where one is available for the lot shipped, yes. The COA is specific to that batch and reports the methods run and the results obtained for it. Availability varies by lot.
How is the material supplied?
As a white to off-white lyophilized powder in a sealed vial, labelled with the compound name and the vial size. The milligram figure is the quantity of peptide in the vial. It is not a potency or a dose.
Do you ship internationally?
Orders ship within the United States. Buyers outside the United States are responsible for their own import rules, and orders may be declined where the compound is restricted.
Terms of Sale and Disclaimers
- Sold for laboratory research, analytical and in vitro use only.
- Not for human consumption, not for veterinary use, and not for any form of administration to a living subject.
- Not evaluated by the Food and Drug Administration. Nothing on this page is intended to diagnose, treat, cure or prevent any disease or condition.
- No statement on this page is a representation that the compound is safe or effective for any use.
- The purchaser is responsible for meeting every federal, state and local requirement that applies to buying, holding, using and disposing of research compounds, and for confirming the compound is lawful in their jurisdiction before ordering.
- By ordering, the purchaser confirms they are a qualified researcher or are buying on behalf of a research organization.
